Ophthotech raises $175 million to fund phase 3 trial of wet AMD drug candidate

With $175 million in financing in place, Ophthotech plans to begin a global phase 3 trial of its lead anti-PDGF compound with anti-VEGF therapy for the treatment of wet age-related macular degeneration, according to a company news release.The trial is slated to begin in the third quarter and will involve almost 1,900 subjects at more than 200 centers globally.

Full Story →